Credit: Canva
Low-dose CT chest scans could help detect pneumonia in at-risk patients while exposing them to only small amounts of radiation, a new study has found. The research, published in Radiology: Cardiothoracic Imaging, shows that ultra-low-dose scans can effectively detect pneumonia in patients with compromised immune systems, enabling doctors to treat the infection before it becomes life-threatening. According to the researchers, these scans expose patients to just 2% of the radiation dose used in a standard CT scan.
"This study paves the way for safer, AI-driven imaging that reduces radiation exposure while preserving diagnostic accuracy,” lead researcher Dr Maximiliano Klug, a radiologist with the Sheba Medical Center in Ramat Gan, Israel, said in a news release. He added that CT scans are the gold standard for detecting pneumonia but there are concerns regarding the risk posed by repeated exposure to radiation. There is a solution- ultra-low-dose CT scan. However, the problem is that these scans can be grainy and hard to read, researchers said.
Study Gives Solution To This
To overcome that, Klug's team developed an AI program that could help "de-noise" low-dose scans, making them sharper and easier to read. Between September 2020 and December 2022, 54 patients with compromised immune systems who had fevers underwent a pair of chest CT scans -- a normal dose scan and an ultra-low-dose scan. The AI program cleaned up the low-dose scan, and then both sets of images were given to a pair of radiologists for assessment. Radiologists had 100% accuracy in detecting pneumonia and other lung problems with the AI-cleaned low-dose scans, but 91% to 98% accuracy in examining the scans that hadn’t been improved through AI, results show.
"This pilot study identified infection with a fraction of the radiation dose," Klug said. "This approach could drive larger studies and ultimately reshape clinical guidelines, making denoised ultra-low dose CT the new standard for young immunocompromised patients.
How Can You Detect Pneumonia?
Pneumonia is a lung infection that causes the air sacs in the lungs to fill with fluid or pus and can be caused by bacteria, viruses, or fungi. The symptoms can range from milk to severe, which includes:
Coughing with or without cough
Fever
Chills
Trouble breathing
Chest pain, especially when breathing deeply or coughing
Sweating or chills
Rapid heart rate
Loss of appetite
Bluish skin, lips, and nails
Confusion.
How to detect Pneumonia in coughing newborns and toddlers?
Pneumonia can severely affect newborns and young children as their lungs are comparatively more sensitive. As per Dr Goyal, young children can cough for various reasons including seasonal infections and tonsillitis, which is very common in this age group. But if they look visibly irritable and have poor sleep patterns, then parents must reach out to an expert. "I am not saying that parents must visit a hospital but any local paediatrician would be able to detect pneumonia in your kid.
Credit: iStock
In a world first, India's indigenous SSI Mantra Surgical Robotic System enabled two surgeons to perform a robotic beating-heart bypass procedure using a dual-console setup, according to SS Innovations.
The five-arm robotic system was used for a Totally Endoscopic Coronary Artery Bypass (TECAB) procedure by two surgeons from Medanta Hospital, Gurugram. The surgeons operated through separate control consoles while the patient's heart continued beating, without the use of a heart-lung machine.
They worked in synchrony using all five robotic arms. A heart stabilization system helped steady the target area during the procedure.
“The successful completion of this highly complex beating-heart TECAB procedure demonstrates how robotic surgery can make advanced cardiac interventions less invasive for patients. It is a proud moment for our team and an important step forward for cardiac surgery in India,” said Dr. Naresh Trehan, Chairman and Managing Director, Medanta.
Unlike conventional robotic cardiac procedures that typically use a single console, a dual-console configuration allows two surgeons to control the robotic system simultaneously. This can improve coordination during complex procedures.
The five-arm configuration allows multiple robotic instruments to be deployed at the same time. It also allows the second surgeon to gain hands-on experience during complex procedures, making the setup potentially useful for surgical training.
Totally Endoscopic Coronary Artery Bypass, or TECAB, is a minimally invasive form of bypass surgery performed through small incisions, without opening the chest through a conventional sternotomy.
In the beating-heart approach, surgeons perform the bypass while the heart continues beating, without stopping it or using a heart-lung machine. A stabilization system keeps the area being operated on steady.
Robotic cardiac surgery also avoids the extensive chest incision involved in conventional open-heart procedures.
The patient's recovery progress over 15 days offers an initial reference point for assessing the outcome. However, longer-term follow-up and clinical data would be needed to establish the broader benefits of this approach.
Dr. Nitin Kumar Rajput, Associate Director of Robotic and Minimally Invasive Cardiac Surgery at Medanta, said performing a complex beating-heart bypass using five robotic arms and two control consoles required precision, coordination and close collaboration between the surgeons.
“The patient's recovery following surgery was encouraging and reinforces the potential of minimally invasive techniques in advancing cardiac care,” he said.
The SSI Mantra is a modular surgical robotic system that can be configured with three to five arms. It features an ergonomic, open-faced Surgeon Command Centre, a 32-inch 3D 4K monitor and a 23-inch touchscreen for patient information.
The system also offers a real-time virtual view of the robotic arms and allows 3D models generated from diagnostic imaging to be superimposed.
Dr. Sudhir Srivastava, Founder, Chairman and CEO of SS Innovations International, Inc., said the procedure demonstrated the SSI Mantra system's potential in minimally invasive cardiac surgery and marked a major milestone for India's surgical robotics sector.
Credit: iStock
Amid rising antimicrobial resistance (AMR) worldwide, the Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under central regulatory oversight.
The amendment seeks to include ‘antimicrobials’ in the definition of ‘New Drug’ under Rule 2(1)(w)(v). Manufacturers would need central approval before applying for a manufacturing licence from state authorities.
"The proposal is intended to serve as an additional regulatory safeguard against antimicrobial resistance (AMR) by strengthening oversight of antimicrobial products and ensuring appropriate scrutiny of their quality, safety and efficacy before the grant of new manufacturing licences," the Ministry said.
AMR occurs when bacteria, viruses, fungi and parasites evolve and no longer respond to medicines designed to treat infections. This makes infections harder to treat, increases the risk of severe illness and death, and can complicate medical procedures such as surgery and cancer treatment.
Addressing the World Antimicrobial Resistance (AMR) Awareness Week 2026, Union Health Secretary Punya Salila Srivastava described AMR as one of the most serious public health challenges. She warned that misuse and overuse of antimicrobials could make even common infections difficult to treat and threaten decades of medical progress.
Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO
The Ministry proposed the amendment through draft Gazette Notification G.S.R. 983 (E), dated November 6.
Manufacturers would need permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the concerned State Licensing Authority (SLA).
Existing manufacturing licences will remain valid, and holders will not need to reapply for permission.
The measure is expected to strengthen central oversight and help ensure the quality, safety and efficacy of antimicrobial products, the Ministry said.
The proposal follows concerns that antimicrobial manufacturing licences are being granted without adequate regulatory scrutiny, including bioavailability/bioequivalence (BA/BE) and stability studies.
The absence of these assessments may affect product quality, safety and efficacy. Substandard or ineffective antimicrobials can contribute to AMR and pose risks to patient safety.
"The measure is part of the Government's broader efforts to promote the responsible use of antimicrobials, safeguard patient safety and address the growing public health challenge of AMR," the Ministry said.
The amendment remains at the draft stage. The Ministry has invited objections and suggestions from stakeholders and the public before finalisation.
In addition, the Ministry has proposed amendments to the Drugs Rules, 1945, to introduce separate application and licence forms for the wholesale sale of bulk drugs, including active and inactive bulk substances.
Currently, a common licence covers the wholesale sale of both formulations and bulk drugs.
The proposed framework would allow more focused oversight of bulk drug sales and improve accountability in the pharmaceutical supply chain, the Ministry said.
Licences would specify the categories of bulk drugs handled by wholesalers, including those covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Bulk drug sales would also require the personal supervision of a competent person.
Credit: iStock
The United States and other countries in the Americas are witnessing increasing influenza activity as the Northern Hemisphere enters the 2026–27 respiratory virus season.
In a November 17 epidemiological alert, the Pan American Health Organization (PAHO) and World Health Organization (WHO) urged countries to strengthen surveillance of respiratory viruses, prepare healthcare services for a possible increase in demand and accelerate seasonal influenza and respiratory syncytial virus (RSV) vaccination among priority groups before the peak of viral circulation.
The report noted that influenza, RSV and other respiratory viruses have gradually increased in the US. Overall respiratory virus activity is higher than typically observed at this time of year.
Influenza positivity increased from 7.6% in the week ending October 18 to 9.1% in the week ending October 25. Influenza A(H1N1)pdm09 emerged as the predominant subtype.
Influenza-like illness (ILI) activity was classified as high in two states, Louisiana and South Carolina. Hospital surveillance data also showed a gradual increase in influenza-associated hospitalisation rates.
Also read: US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch
Canada is also witnessing an increase in influenza circulation, which began earlier than in previous post-pandemic seasons between 2022–23 and 2025–26.
Influenza positivity reached 10.8% in the week ending October 25, with activity shifting from low to moderate levels. Unlike the previous season, influenza A(H1N1)pdm09 is the predominant subtype.
COVID-19 circulation is also gradually increasing in Canada but remains low and below levels observed in previous seasons. SARS-CoV-2 positivity stood at 5.8%.
Hospitalisations associated with respiratory viruses are also rising, reaching 2.6 per 100,000 population. Influenza-associated hospitalisations reached 1.2 per 100,000, while the rate for COVID-19-associated hospitalisations was 1.3 per 100,000. However, PAHO/WHO noted that these rates remain low and within the expected range for this time of the season.
Read More: G155E H1N1 Mutation In US Raises Concerns: Can This Year’s Flu Shot Still Protect You?
Globally, influenza activity is following expected seasonal patterns, with a gradual increase over recent months in temperate and subtropical regions of the Northern Hemisphere. Influenza positivity in these regions is approaching 10%.
Some countries in North America, Central America and the Caribbean, as well as in Africa, Asia and Europe, have reported influenza positivity rates above 10%, according to the alert.
In contrast, influenza activity has declined over the past two months in temperate and subtropical regions of the Southern Hemisphere, where positivity has fallen to around 5%.
READ: Flu 2026: Symptoms To Watch For As New Season Begins
Alongside increasing influenza activity, PAHO/WHO highlighted high RSV circulation in some countries in the Northern Hemisphere.
Globally, RSV positivity rates above 10% were observed in some countries, particularly in tropical and subtropical regions.
The organization warned that the circulation of multiple respiratory viruses makes it important for countries to strengthen healthcare preparedness ahead of seasonal peaks.
PAHO/WHO has called on member states to strengthen integrated epidemiological and virological surveillance of respiratory viruses, including timely genomic characterization to monitor viral evolution.
It has also recommended that countries adjust healthcare preparedness and organizational plans in anticipation of a possible increase in demand for medical services.
The alert also urges countries to accelerate seasonal influenza and RSV vaccination among priority groups, in line with current recommendations and before periods of increased viral circulation.
© $2026 Times Horizon Private Limited